Shopping Cart 0
Cart Subtotal

MagForce AG (MF6) - Product Pipeline Analysis, 2018 Update

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 750

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 1500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 2250
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies



MagForce AG (MagForce) is a medical device company that offers nanotechnology-based therapy for cancer treatment. The company's products include NanoActivator, NanoTherm, NanoPlan and NanoTherm Therapy. Its NanoActivator creates a magnetic field that can be used to treat tumors in all areas of the body. MagForce's NanoTherm is a liquid that reacts to the presence of magnetic field. The company's NanoPlan uses the bioheat transfer equation to help the physician in charge estimate treatment temperatures and the magnetic field strength. Its products are used in the treatment of prostate cancer, pancreatic cancer, esophageal cancer and glioblastoma. The company operates through therapy centers located in Berlin, Munster, Kiel, Cologne and Frankfurt, Germany. MagForce is headquartered in Berlin, Germany.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.


- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company MagForce AG

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company


Table Of Content


Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

MagForce AG Company Overview 4

MagForce AG Company Snapshot 4

MagForce AG Pipeline Products and Ongoing Clinical Trials Overview 4

MagForce AG-Pipeline Analysis Overview 6

MagForce AG-Key Facts 6

MagForce AG-Major Products and Services 7

MagForce AG Pipeline Products by Development Stage 8

MagForce AG Ongoing Clinical Trials by Trial Status 10

MagForce AG Pipeline Products Overview 11

NanoTherm-Brain Cancer 11

NanoTherm-Brain Cancer Product Overview 11

NanoTherm-Gastrointestinal Cancer 12

NanoTherm-Gastrointestinal Cancer Product Overview 12

NanoTherm-Pancreatic Carcinoma 13

NanoTherm-Pancreatic Carcinoma Product Overview 13

NanoTherm-Prostate Carcinoma 14

NanoTherm-Prostate Carcinoma Product Overview 14

NanoTherm-Prostate Carcinoma Clinical Trial 15

NanoTherm-Recurrent Glioblastoma 16

NanoTherm-Recurrent Glioblastoma Product Overview 16

Next-Generation Nanotherm 17

Next-Generation Nanotherm Product Overview 17

MagForce AG-Key Competitors 18

MagForce AG-Key Employees 19

MagForce AG-Locations And Subsidiaries 20

Head Office 20

Other Locations & Subsidiaries 20

Recent Developments 21

MagForce AG, Recent Developments 21

Jul 02, 2018: MagForce Announces Enrollment of First Patient in its Pivotal, Three-Stage, Single-Arm Study of Focal Ablation of Prostate Cancer with NanoTherm Therapy 21

Jun 14, 2018: MagForce Co-Sponsors the University Hospital of Munster's Annual Brain Cancer Patient Event 21

Jun 12, 2018: MagForce Announces Collaboration Agreement for NanoTherm Therapy with Independent Public Clinical Hospital No. 4, Lublin, Poland 22

Jun 04, 2018: MagForce to host Lunch Symposium about Local Therapies for Malignant Gliomas at the 2018 meeting of the German Society of Neurosurgery (DGNC) 23

May 03, 2018: MagForce Publishes Financial Results for the Year 2017 and Operative Highlights 23

Feb 15, 2018: FDA expands treatment window for use of clot retrieval devices in certain stroke patients 25

Feb 10, 2018: MagForce USA Receives FDA Investigational Device Exemption Approval to Conduct A Clinical Trial With NanoTherm Therapy As Focal Ablation Treatment For Intermediate Risk Prostate Cancer 26

Nov 14, 2017: MagForce to participate at SNO 2017 Annual Meeting from November 16-19 in San Francisco, USA 27

Sep 29, 2017: MagForce Publishes Financial Results for the First Half of 2017 and Operative Highlights 28

Aug 10, 2017: MagForce announces positive results of 2017 Annual General Meeting 30

Appendix 31

Methodology 31

About GlobalData 34

Contact Us 34

Disclaimer 34

List Of Figure

List of Figures

MagForce AG Pipeline Products by Equipment Type 5

MagForce AG Pipeline Products by Development Stage 8

MagForce AG Ongoing Clinical Trials by Trial Status 10

List Of Table

List of Tables

MagForce AG Pipeline Products and Ongoing Clinical Trials Overview 4

MagForce AG Pipeline Products by Equipment Type 5

MagForce AG Pipeline Products by Indication 5

MagForce AG Ongoing Clinical Trials by Trial Status 5

MagForce AG, Key Facts 6

MagForce AG, Major Products and Services 7

MagForce AG Number of Pipeline Products by Development Stage 8

MagForce AG Pipeline Products Summary by Development Stage 9

MagForce AG Ongoing Clinical Trials by Trial Status 10

MagForce AG Ongoing Clinical Trials Summary 10

NanoTherm-Brain Cancer-Product Status 11

NanoTherm-Brain Cancer-Product Description 11

NanoTherm-Gastrointestinal Cancer-Product Status 12

NanoTherm-Gastrointestinal Cancer-Product Description 12

NanoTherm-Pancreatic Carcinoma-Product Status 13

NanoTherm-Pancreatic Carcinoma-Product Description 13

NanoTherm-Prostate Carcinoma-Product Status 14

NanoTherm-Prostate Carcinoma-Product Description 14

NanoTherm-Prostate Carcinoma-An Investigational Device Exemption, Phase III Study of NanoTherm therapy as Focal Ablation Treatment for Intermediate Risk Prostate Cancer 15

NanoTherm-Recurrent Glioblastoma-Product Status 16

NanoTherm-Recurrent Glioblastoma-Product Description 16

Next-Generation Nanotherm-Product Status 17

Next-Generation Nanotherm-Product Description 17

MagForce AG, Key Employees 19

MagForce AG, Other Locations 20

MagForce AG, Subsidiaries 20

Glossary 33

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to

Products and Companies


MagForce AG, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies


Draegerwerk AG & Co. KGaA

Curetis NV

Pulsion Medical Systems SE

German Cancer Research Center